Expansion of an originally very minor JAK2 V617F mutated cell subset (variant allele frequency at AML diagnosis: 0.6%) was observed as a response to selection pressure conferred by multiple lines of chemotherapy and isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib treatment. The gene discussed is IDH1; the disease is acute myeloid leukemia.